In the past, the healthcare industry could never have visualized some standard devices today. Say, pocket-sized scanning devices, robots performing surgeries, or a myriad of technological innovations, including artificial intelligence, AR, VR, cloud, and so on. It is beyond doubt that these technologies are reshaping the medical industry, turning it future-ready. The need for innovative solutions and medicines will always be an integral part of the healthcare industry. Therefore, the sector is always in search of innovative medications or solutions. Enter AbbVie, intending to discover and deliver innovative solutions and medicines. The efforts by AbbVie would focus on dealing with complex health conditions with an ‘out-of-the-box’ approach.

AREAS OF FOCUS

AbbVie strives toward innovation and their expertise reflects on immunology, Neuroscience, oncology, aesthetics, and eye care. AbbVie has been able to discover some innovative approaches in the treatment of cancer. In addition, the knowledge earned over the years is now being leveraged to treat solid tumors. The firm is a trusted name in treating people with an immune-mediated illnesses.

AbbVie already extensively focuses on neurodegenerative diseases, specifically ocular surface illness, and retina-related issues. The genetic basis is being analyzed deeply to understand the basics to bring in innovative approaches. The goal is to reduce the treatment burden on patients. The other area of focus is aesthetic medicine. AbbVie intends to hasten and identify the development of comprehensive solutions that are scientifically powered.

“In the field of neuroscience, with many toughto-treat disorders and high unmet needs, our scientists are relentless in their pursuit of raising the standards of care. But the brain is complex, and new challenges require new ways of thinking across all drug discovery and development stages. That’s why we are continuously exploring innovative, disease-modifying approaches to address some of the most prevalent and serious disorders, from Parkinson’s and Alzheimer’s to migraine, schizophrenia, and stroke,” informs Richard A. Gonzalez, CEO.

Besides these core therapeutic areas, AbbVie extends its research to various other sectors. The common aspect of these sectors is that each is critical for the healthcare industry and includes enormous innovation potential. “Our teams are advancing the research and development for diseases that share one commonality — we believe that innovation will lead to discoveries.

Areas of interest include Hepatitis C, HIV, COVID-19, pulmonology, endocrinology, gastrointestinal diseases, and therapeutic neurotoxins. Our scientific talent and experience are as diverse as the diseases we study. Together, we work globally to incubate and advance strategies to help bring medicines and solutions to needy adults and children. We are investigating direct-acting antivirals for the treatment of COVID-19,” adds the CEO.

THE PATIENT SUPPORT PROGRAMS

“At AbbVie, patients are at the heart of what we do: creating medicines and solutions that make a difference in people’s lives. We partner with patients, patient organizations, caregivers, and clinicians to ensure that individual experiences, perspectives, needs, and priorities are part of our clinical development process,” explains CEO.

The firm emphasizes medicines being affordable to all as required. AbbVie has planned several support and access programs. Through disease knowledge and resource access, our patient support programs enable patients on prescribed medications to benefit from their treatments fully. The educational programs are designed to empower patients with helpful information or awareness on effectively managing their diseases.

In addition, the families and caretakers of the patients are also involved in the process. Currently, AbbVie includes more than 50,000 employees spread across seventy countries. More than 60 health conditions are treated globally and at different stages of life.

Enter AbbVie, intending to discover and deliver innovative solutions and medicines. The efforts by AbbVie would focus on dealing with complex health conditions with an ‘out-of-the-box’ approach.